RT Journal Article
SR Electronic
T1 Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1259
OP 1265
VO 32
IS 4
A1 CHANG, JOHN WEN-CHENG
A1 WEI, NIEN-CHIH
A1 SU, HUNG-JU
A1 HUANG, JIE-LEN
A1 CHEN, TSE-CHING
A1 WU, YI-CHENG
A1 YU, CHIH-TENG
A1 HOU, MING-MO
A1 HSIEH, CHIA-HSUN
A1 HSIEH, JIA-JUAN
A1 WU, CHIAO-EN
A1 CHENG, HSIN-YI
A1 HSU, TODD
A1 WANG, TZU-HAO
YR 2012
UL http://ar.iiarjournals.org/content/32/4/1259.abstract
AB Background: Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence. Materials and Methods: We analyzed gene expression in frozen lung cancer tissue from 59 selected patients who had undergone surgical resection of NSCLC. These patients were divided into two groups: group R, patients who had a tumor recurrence within four years, n=37; group NR, patients who remained disease-free four years following initial surgery, n=22. Each RNA sample was assayed twice using both Affymetrix and Illumina GeneChip. Data were analyzed by principal component analysis and leave-one-out cross-validation. Results: Using the same filtering criteria, 13 genes that were differentially expressed between R and NR were identified by Affymetrix, while 21 genes were identified by Illumina GeneChip. In common, a total of six genes were detected by both systems. Using univariate analysis, four (lipocalin 2, LCN2; parathyroid hormone-like hormone, PTHLH; ras-related protein Rab-38, RAB38; and four jointed box 1, FJX1) of these six genes were associated with survival. A risk score of survival was calculated according to the four-gene expression. There was a significant difference in overall survival between low- and high-risk groups. Conclusion: A four-gene signature is associated with survival among patients with early-stage NSCLC. Further validation of these findings is warranted.